Industry NewsLife Sciences
Breast cancer tops most-studied diseases list for fourth year but trial attrition rate rises, finds new Phesi analysis
1 in 3 Phase II trials were terminated in 2024
1 in 3 Phase II trials were terminated in 2024
The UG 100 offers a cost-effective and extremely low-error sequencing profile
Dive into a new era of intelligence and performance with Agilent's upcoming virtual launch
By developing rapid, accurate, and cost-effective lateral flow tests for prostate cancer, Valley Diagnostics aims to make early diagnosis more accessible and reliable
Enhances quality control by providing absolute molecular weight of biologics and avoiding common errors encountered with other techniques
Drug Discovery returns to Liverpool, 21–22 October 2025 to celebrate 'A Festival of Life Science'
The Adeno-Associated Virus will be used in a Phase 1 trial in patients with advanced, high-risk acute myeloid leukemia.